John Wayne Cancer Institute Researchers Identify Epigenomic Test That Could Improve Treatment for Specific Gastric Cancers

SANTA MONICA, Calif.--(BUSINESS WIRE)--A study by researchers at the John Wayne Cancer Institute at Saint John’s Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome. The study suggests that inhibiting COX-2 with readily available drugs may improve outcomes for some gastric cancer patients.